CRH ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 310 | Congenital anomalies syndrome | 1 |
310. Congenital anomalies syndrome
Clinical trials : 11 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001721 (ClinicalTrials.gov) | September 13, 1998 | 3/11/1999 | Study of Smith-Lemli-Opitz Syndrome | Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome | Smith-Lemli-Opitz Syndrome | Drug: Cholesterol Suspension;Drug: CRH;Drug: Cholesterol | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | N/A | N/A | All | 130 | United States |